Patel Sushil sold $510K of REPL

Patel Sushil (Chief Executive Officer) sold 39,341 shares of Replimune Group, Inc. (REPL) at $12.97 ($0.51M total) on 2026-08-10.

Original reporting
SEC EDGAR · Patel Sushil
Published Aug 12, 2026, 9:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$REPL
Neutral
medium confidence
Mentioned
$REPL
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$REPLNeutralLow
01

Why it matters

Traders may treat the CEO sale as a mild negative sentiment input, but without additional company news it is unlikely to drive a sustained repricing.

02

Market read

A newly filed insider sale provides incremental sentiment information for REPL, but no fundamental catalyst is disclosed.

03

What to watch

The article does not state whether the sale was part of compensation, tax planning, or other non-informational motives, and it provides no 10b5-1 plan details.

Relevance 5/10Novelty 5/10Timing: Form 4 filed 2026-08-12, covering sale dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for Replimune Group, Inc.

Company-level read

Ticker impact

$REPLNeutralMedium confidence
Context

Replimune CEO Patel Sushil sold 39,341 shares on 2026-08-10 for about $510,252, per a newly filed Form 4.

Expected impact

Near-term impact likely limited, with any effect more sentiment-driven than fundamental.

Evidence & confidence

The filing is primary-source and time-stamped, but it is an open-market sale with no 10b5-1 plan disclosed and no accompanying company-specific operational or guidance change.

Market effects

No sector-wide implication is provided; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

The sale could be routine liquidity management and may not signal reduced confidence, especially without any stated linkage to company events.

Key entities

  • Replimune Group, Inc.

    US-listed company whose CEO filed an insider sale on Form 4.

  • Patel Sushil

    Chief Executive Officer and officer/director who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$REPLHigh

Replimune Soars 17% as TUDRIQEV Melanoma Launch Draws “Enthusiastic” Response From Physicians

Replimune (REPL) shares rose 17% after reporting strong initial uptake of TUDRIQEV, its melanoma treatment, with over 15 institutions prescribing it in three weeks. The company has $307.8 million in cash. TUDRIQEV is used with Bristol Myers Squibb's (BMY) Opdivo and targets tumors not treated by Amgen's (AMGN) Imlygic. Analysts expect revenue growth, but no sales figures are available yet.

$REPLMed

Replimune (REPL) Q2 2027 Earnings Call Transcript

Replimune (REPL) reported Q2 2027 earnings, highlighting the commercial launch of TUDRIQEV. The company noted strong physician interest and rapid adoption, with over 15 institutions prescribing the drug in less than 20 business days. Replimune reported a net loss of $57.1 million for the quarter, with $307.8 million in cash reserves. The company expects to report first product revenue in Q3 2027.

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$REPLMed

Replimune Reports Fiscal Q2 2027 Results, $57.1 Million Net Loss

Replimune reported a net loss of $57.1M for Q2 2027, down from $83.1M a year earlier. Cash reserves were $307.8M. R&D and operating expenses decreased. TUDRIQEV, for advanced melanoma, launched commercially in the U.S. in October, with over 15 institutions prescribing it. The company is engaging with priority accounts and advancing clinical trials.